Should I Buy ARMP? ARMP 2026 Analysis

Should You Buy Armata Pharmaceuticals Inc (ARMP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

7.700

1 Day change

-4.70%

52 Week Range

16.340

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: the chart is extended (RSI6 ~79.7) and price is already above the first resistance (R1=7.505) with the next resistance close (R2=7.989), which increases near-term pullback risk.
Trend is bullish (SMA_5 > SMA_20 > SMA_200 and MACD histogram expanding), but there is no Intellectia edge today (no AI Stock Picker / SwingMax), and the pattern-based forecast skews slightly negative over the next month.
Wall Street is constructive (recent Buy initiation, PT $15), but fundamentals remain weak (2025/Q3 revenue -61% YoY and large net loss), so the setup is more speculative momentum than fundamentally supported.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock today.

Technical Analysis

Trend: Bullish structure with moving averages aligned positively (SMA_5 > SMA_20 > SMA_200).
Momentum: MACD histogram at 0.146 and expanding above zero (bullish momentum still building).
Overbought/extension: RSI_6 at 79.684 (overheated/extended short-term condition).
Key levels: Pivot 6.722; Support S1 5.939 (then S2 5.455). Resistance R1 7.505 (already exceeded pre-market at ~7.6), next resistance R2 7.989 (nearby).
Price context: Pre-market ~7.6 suggests strength, but buying into resistance after an overbought reading is a lower-quality entry for a quick trade.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Open interest put/call ratio 1.22 (slightly defensive/hedged positioning).
Flow today: Put volume is 0 while call volume is 43 (flow skewed to calls, but overall volume is not large).
Volatility: 30D IV ~251% vs historical vol ~232%; IV percentile ~10 and IV rank ~15.7 (IV is low relative to its own recent distribution, despite being very high in absolute terms).
Interpretation: Sentiment is mixed—OI leans cautious, but today’s trading activity is call-only; nothing here screams “must-buy now.”

Technical Summary

Sell

Buy

Positive Catalysts

- Technical uptrend remains intact (bullish MA stack + positive, expanding MACD).
- Analyst catalyst: JonesResearch initiated with Buy and $15 PT (supports upside narrative around phage platform and in-house cGMP manufacturing).
- No negative news flow in the last week (no fresh headline overhang reported).

Neutral/Negative Catalysts

- Short-term stretched: RSI near ~80 and price pushing into/above resistance (R1 passed; R2 nearby) increases odds of a near-term dip.
- No proprietary timing signal today (no AI Stock Picker pre-market buy / no SwingMax entry), reducing conviction for an “enter immediately” decision.
- Fundamentals still weak: 2025/Q3 revenue down sharply YoY; large net loss persists.
- Quant/pattern read-through: similar-pattern projection shows mild negative bias over the next month (-1.68%).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: $1.159M, down -61.02% YoY (material top-line contraction).
Profitability: Net income -$26.675M (still a large loss; YoY change indicates the loss widened versus prior year).
EPS: -$0.74 (still deeply negative; YoY change indicates a larger loss per share versus prior year).
Gross margin: 100% (not very informative here given the low revenue base; core issue is scale and operating losses).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent change: 2026-01-05 JonesResearch initiated coverage at Buy with a $15 price target.
Wall Street pros: Differentiated phage therapy platform + in-house cGMP manufacturing capability; clear focus on hard-to-treat infections (Staph aureus bacteremia, Pseudomonas).
Wall Street cons: Clinical-stage risk profile and currently weak financial trajectory (shrinking revenue base and ongoing heavy losses).
Positioning/trading activity context: Hedge funds and insiders are reported as neutral; no recent congress trading data available.

2 Analyst Rating

Wall Street analysts forecast ARMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARMP is 12 USD with a low forecast of 9 USD and a high forecast of 15 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 8.080

Low

Averages

High

Current: 8.080

Low

Averages

High

JonesResearch

Debanjana Chatterjee

Buy

initiated

$15

AI Analysis

2026-01-05

Reason

JonesResearch

Debanjana Chatterjee

Price Target

$15

AI Analysis

2026-01-05

initiated

Buy

Reason

JonesResearch analyst Debanjana Chatterjee initiated coverage of Armata Pharmaceuticals with a Buy rating and $15 price target. What differentiates Armata from other companies developing clinical-stage phage therapies is the combination of a proprietary off-the-shelf phage platform and in-house cGMP manufacturing that can consistently produce high-purity, high-titer, clinical-grade phage cocktails, the analyst tells investors. Armata is developing AP-SA02 and AP-PA02 against difficult-to-treat Staph. aureus bacteremia and Pseudomonas aeruginosa infections, respectively, the analyst noted.

H.C. Wainwright

Buy

maintain

2025-10-22

Reason

H.C. Wainwright

Price Target

2025-10-22

maintain

Buy

Reason

H.C. Wainwright reiterates a Buy rating and $9 price target on Armata Pharmaceuticals after the company shared new data from the recently completed Phase 2a diSArm study in a late-breaking oral presentation at IDWeek 2025. These new in vitro data providing strong evidence for the efficacy of its core therapeutic strategy for AP-SA02, along with the broader dataset, support advancement into a pivotal Phase 3 trial set to begin in 2026, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ARMP

Unlock Now

ARMP Should I Buy

ARMP Should I Buy

Should You Buy Armata Pharmaceuticals Inc (ARMP) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch